Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 19/20 | 0.83 |
| ▸ | KIT | P10721 | 4/20 | 0.75 |
| ▸ | KDR | P35968 | 12/20 | 0.68 |
| ▸ | MET | P08581 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091938 | 0.91 | PDGFRA (1.00) | PDGFRAKITKDRMETHDAC1 | |
| SCHEMBL1875152 | 0.91 | PDGFRA (0.72) | PDGFRAKITKDRMETHDAC1 | |
| SCHEMBL5092881 | 0.89 | PDGFRA (0.90) | PDGFRAKITKDRMETHDAC1 | |
| SCHEMBL4473561 | 0.86 | PDGFRA (1.00) | PDGFRAKITKDRMETHDAC1 | |
| SCHEMBL5824748 | 0.85 | PDGFRA (0.83) | PDGFRAKITKDRMETHDAC1 | |
| SCHEMBL5824898 | 0.85 | PDGFRA (0.83) | PDGFRAKITKDRMETHDAC1 | |
| SCHEMBL6228071 | 0.84 | PDGFRA (0.80) | PDGFRAKDR | |
| SCHEMBL5824663 | 0.84 | PDGFRA (0.82) | PDGFRAKITKDRMET | |
| SCHEMBL29973354 | 0.84 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL27081475 | 0.84 | PDGFRA (0.95) | PDGFRAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1566379-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | PDGFRA 229/4885KIT 171/4885KDR 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.